[A24-84] Risankizumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2024
Project no.:
A24-84
Commission:
Commission awarded on 20.08.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Adults with moderately to severely active ulcerative colitis
Result of dossier assessment:
- Patients who have had an inadequate response to, lost response to, or were intolerant to conventional therapy: added benefit not proven
- Patients who have had an inadequate response to, lost response to, or were intolerant to a biologic therapy: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-84_en
| Project no. | Title | Status |
|---|---|---|
| A22-133 | Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V | Commission completed |
| A21-156 | Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-41 | Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |